|
Proceedings
Day 1 - Monday, October 19, 2004
Overview
Objectives, Format & Opening Remarks
Steven A. Hofstadler, Ibis Therapeutics
Mark Sanders, Bristol-Myers Squibb
Plenary
Quantitative and Ultra-sensitive High Throughput Proteomics
Richard D. Smith, Pacific Northwest National Laboratory
Roundtable Discussion
Biomarkers - Initiatives, Perspectives & Approaches
Discussion Leaders: Bradley L. Ackermann, Eli Lilly and Company
Sushmita M. Roy, SurroMed
An Industrial Perspective on Biomarker Research: One Approach Taken
Stanley Hefta, Bristol-Myers Squibb
Biomarkers of Oxidative Stress
Ian Blair, University of Pennsylvania
Roundtable Discussion
How to We Set Priorities in Drug Discovery and Development
Discussion Leader: Mike S. Lee, Milestone Development Services
Bradley Ackermann, Eli Lilly and Co.
Edward Brewer, Tandem Labs
Chandra Natarajan, Sanofi Aventis
Steve Unger, Bristol-Myers Squibb
Outsourcing Trends - Emerging Business Models & Overseas
Partners
Discussion Leader: Roger Hayes, Schering Plough Research
Institute
The Impact of Value Enhancement Initiatives to Outsourcing Strategies
Roger Hayes, Schering Plough Research Institute
Outsourcing and Offshoring DMPK Studies - The Pros and Cons
Zamas Lam, Quest Pharmaceutical Services
Cost Benefit Analysis
Mickey O'Brien, Tandem Labs
Roundtable Discussion
High Throughput Analysis & Information Management
Strategies
Discussion Leader: Eric A. Milgram, Advanced Chemistry Development
Flexible Automation Tools for Drug Metabolism: Workstation and Fully
Automated Approaches for in vitro and PK Studies
Tom Lloyd, H. Kandoussi and R. Talaat, Wyeth
Automatic Reduction of Analytical Data System
Kenneth Lewis, Eli Lilly and Company
High-Throughput LC-MS – A Total Package
Manish Soni, Aventis Pharmaceuticals
Roundtable Discussion
Vendor/Exhibitor Sessions:
Discussion Leader: Kathleen Anderson, Novatia
Poster Sessions
Chairs:
Praveen Balimane, Bristol-Myers Squibb
Manish Soni, Aventis Pharmaceuticals
James Stephenson, Research Triangle Institute
|